Adagio Medical (NASDAQ:ADGM – Get Free Report) issued its earnings results on Monday. The company reported ($5.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($7.40) by $2.27, reports.
Adagio Medical Price Performance
ADGM stock traded down $0.11 during trading on Monday, reaching $1.82. 25,711 shares of the company were exchanged, compared to its average volume of 105,536. The company has a 50-day moving average of $6.41 and a two-hundred day moving average of $21.21. The company has a market capitalization of $50.39 million, a price-to-earnings ratio of -0.04 and a beta of 0.07. Adagio Medical has a twelve month low of $1.50 and a twelve month high of $50.70. The company has a debt-to-equity ratio of 4.00, a current ratio of 1.41 and a quick ratio of 1.15.
Analyst Ratings Changes
Separately, Weiss Ratings cut Adagio Medical from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 19th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Adagio Medical has an average rating of “Hold” and a consensus price target of $105.00.
View Our Latest Research Report on ADGM
About Adagio Medical
Adagio Medical is a medical technology company developing catheter-based systems for treating cardiac arrhythmias. Its technology uses ultra-low-temperature cryoablation, which applies very cold temperatures to create lesions in heart tissue that can interrupt abnormal electrical signals. The company’s platform includes the vCLAS system, designed for ventricular arrhythmias such as ventricular tachycardia, and the iCLAS system, designed for atrial fibrillation. These systems are intended for use in catheter ablation procedures by cardiac electrophysiology teams.
Read More
- Five stocks we like better than Adagio Medical
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
- 3 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
Receive News & Ratings for Adagio Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adagio Medical and related companies with MarketBeat.com's FREE daily email newsletter.
